© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor

PharmaVitae: Amgen Inc. HC Slidepack 06/11 quality dataexpert analysisintuitive delivery the home of Business Intelligence

Amgen prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

Amgen financial performance ($m), 2004–16

SWOT analysis of Amgen Growing fiscally in a period of sales decline Considerable marketing strength and experience for a biotech Strong intellectual property rights (IPR) position Strengths Limited presence in the emerging markets Biosimilar sales erosion in the EU and RoW Weaknesses Denosumab (Prolia/Xgeva) offering therapy area and technology type diversification Geographic expansion: more acquisitions to tap into the emerging markets In-licensing of late stage pipeline candidates Opportunities Biosimilar introduction into the US Threats

Restructuring initiatives Stuttering revenue growth: operating profit growth Xgeva driven revenue growth: operating profit grows in line Profitable business model ensures growth despite level-off 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20, Sales/cost ($m) RevenuesTotal costsOperating profit Amgen’s total revenue, cost and operating profit performance ($m),

Sales growth by molecule type ($m),

Average Operating profit performance of ‘top tier’ pharmaceutical companies (sales in excess of $8bn in 2010), ($m)

1980: AMGen (Applied Molecular Genetics) established in California 1983: Initial public offering – raises $40 million 1987: Amgen receives patent on DNA used in producing epoetin alpha 1989: FDA approves Epogen (epoetin alpha) 1991: FDA approves Neupogen (filgrastim) for the treatment of neutropenia 1998: FDA approves Enbrel (etanercept) for the treatment of rheumatoid arthritis 2001: FDA approves Aranesp (darbepoetin alpha) 2002: FDA approves Neulasta (pegfilgrastim) 2002: Amgen completes Immunex acquisition 2004: FDA approves Sensipar (cinacalcet) 2004: Amgen completes the acquisition of Tularik 2006: Amgen completes the acquisition of Abgenix 2006: FDA approves Vectibix (panitumumab) 2007: Amgen acquires Alantos and Ilypsa 2007: Amgen announces major restructuring initiatives 2008: Takeda purchases a number of pipeline candidates to develop for Japan 2009: Amgen launches Nplate (romiplostim) 2010: Amgen launches Prolia and Xgeva (denosumab) 2011: Amgen acquires Brazilian company Bergamo 1980s 1990s 2000s Amgen timeline

AmgenSynergenImmunexTularikAbgenixAlantosIlypsaBergamo AmgenSynergenImmunexTularikAbgenixAlantosIlypsa AmgenSynergenImmunexTularikAbgenix AmgenSynergenImmunexTularik AmgenSynergenImmunex AmgenSynergen Amgen Amgen M&A history

Amgen corporate structure

Amgen prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

Key product sales ($m), 2004–16

Amgen key product growth drivers and resistors ($m), 2004–10

Amgen key product growth drivers and resistors ($m), 2010–16

Amgen prescription pharmaceutical sales by therapy area ($m), 2004–16

Amgen prescription pharmaceutical sales by geographic region ($m), 2004–16

Amgen launch, core and expiry configuration, sales ($m), 2010–16

Amgen prescription pharmaceutical sales by molecule type ($m), 2004–16

Amgen prescription pharmaceutical sales by source of product ($m), 2004–16

Amgen operating revenue/cost analysis ($m), 2004–16

Neulasta sales by geographic region ($m), 2004–16

Xgeva sales by geographic region ($m), 2004–16

Enbrel sales by geographic region ($m), 2004–16

Aranesp franchise sales by geographic region ($m), 2004–16

Epogen franchise sales by geographic region ($m), 2004–16

Prolia sales by geographic region ($m), 2004–16

Amgen operating revenue/cost analysis ($m), 2004–16

Amgen’s pipeline by therapy area

© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor